Development of Quality of Life Questionnaire in Japan: quality of life assessment of cancer patients receiving chemotherapy

Kurihara, Minoru; Shimizu, Hiroyuki; Tsuboi, Koji; Kobayashi, Kunihiko; Murakami, Minoru; Eguchi, Katsumi; Shimozuma, Kojiro

doi:10.1002/(sici)1099-1611(199907/08)8:4<355::aid-pon401>3.0.co;2-i

Cited by 104 publications

(54 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Health-related quality of life (QOL) was assessed experimentally with a self-administered QOL questionnaire for cancer patients treated with anticancer drugs (QOL-ACD) (Kurihara et al, 1999). The QOL-ACD was completed at baseline, every week during treatment and every month after treatment.…”

Section: Discussionmentioning

confidence: 99%

Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer

Negoro

Masuda

Takada³

et al. 2003

Br J Cancer

136

109

View full text Add to dashboard Cite

To determine a standard combination chemotherapy for patients with advanced non-small-cell lung cancer (NSCLC), we conducted a phase III trial of irinotecan (CPT-11) to test the hypotheses that CPT-11+cisplatin is superior to cisplatin+vindesine and that CPT-11 monotherapy is not inferior to cisplatin+vindesine. A total of 398 patients with previously untreated NSCLC were randomised to receive cisplatin+CPT-11 (CPT-P), cisplatin+vindesine (VDS-P) or CPT-11 alone (CPT). In the CPT-P arm, CPT-11 60 mg m À2 was administered on days 1, 8 and 15, and cisplatin 80 mg m À2 was administered on day 1. In the VDS-P arm, cisplatin 80 mg m À2 was administered on day 1, and vindesine 3 mg m À2 was administered on days 1, 8 and 15. In the CPT arm, CPT-11 100 mg m À2 was administered on days 1, 8 and 15. The median survival time was 50.0 weeks for patients on CPT-P, 45.6 weeks for those on VDS-P and 46.0 weeks for those on CPT (P ¼ 0.115, CPT-P vs VDS-P; P ¼ 0.089, CPT vs VDS-P), and the hazard ratio was 0.85 (95% confidence interval (CI): 0.65 -1.11) for CPT-P vs VDS-P and 0.83 (0.64 -1.09) for CPT vs VDS-P. The response rate was 43.7% for patients on CPT-P, 31.7% for those on VDS-P and 20.5% for those on CPT. Major adverse reactions were grade 4 neutropenia observed in 37, 54 and 8% of the patients on CPT-P, VDS-P and CPT, respectively; and grades 3 and 4 diarrhoea observed in 12, 3 and 15% of the patients, respectively. CPT-P therapy produces comparable survival to VDS-P in patients with advanced NSCLC. CPT-11 monotherapy is not inferior to VDS-P in terms of survival. The CPT-11-containing regimen is one of the most efficacious and well tolerated in the treatment of advanced NSCLC.

show abstract

Section: Discussionmentioning

confidence: 99%

Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer

Negoro

Masuda

Takada³

et al. 2003

Br J Cancer

136

109

View full text Add to dashboard Cite

show abstract

“…It was estimated that 300 patients would be an adequate sample size to accurately assess CIPN and HRQOL following review of the validation studies for Fig. 1 The Patient Neurotoxicity Questionnaire several major cancer-specific HRQOL instruments such as the EORTC QOL-Core 30 (N=305) [1], FACT-G (N=545) [7], and the QOL Questionnaire for patients treated with Anti-Cancer Drugs (QOL-ACD) (N=212) [15].…”

Section: Statistical Considerationsmentioning

confidence: 99%

Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02

Shimozuma

Ohashi

Takeuchi

et al. 2009

Support Care Cancer

Self Cite

173

128

View full text Add to dashboard Cite

The PNQ has an applicable degree of feasibility and validity, useful for the diagnosis of CIPN as well as for clinical treatment decision-making, where the development of CIPN is a potential treatment-limiting consideration. Physicians underreport and underestimate the severity of CIPN symptoms compared with patients, thereby supporting the importance of assessing patient-reported outcomes using the PNQ.

show abstract

“…A 5-point scale was used to evaluate CVD-site itching, with 0 indicating no itching and 5 indicating the most intense itching possible. 11) Blood Sample Collection A 6-mL blood sample was collected from each participant. Plasma was fractionated from collected blood samples by centrifugation at 10000×g for 10 min at 4°C.…”

Section: Methodsmentioning

confidence: 99%

Sex Differences of the Inflammatory Mediator Level at the Time of Itch Onset in Patients with Chronic Venous Disease

et al. 2018

View full text Add to dashboard Cite

This study investigated the sex diŠerences of the in‰ammatory mediator level at the time of itch onset in patients with chronic venous disease (CVD). Twenty-seven CVD patients (nineteen women, eight men) and nine healthy controls (ˆve women, four men) participated. CVD-associated itching was observed in both men and women. Before sclerotherapy, both sexes had elevations in several itch-related mediators. Among these, women had signiˆcantly higher tryptase, whereas men had signiˆcantly higher b-endorphin and adrenocorticotropic hormone. After sclerotherapy, all levels normalized in both sexes. In this study, itching was increased tryptase in women and increased adrenocorticotropic hormone and b-endorphin in men.

show abstract

Development of Quality of Life Questionnaire in Japan: quality of life assessment of cancer patients receiving chemotherapy

Cited by 104 publications

References 8 publications

Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer

Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer

Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02

Sex Differences of the Inflammatory Mediator Level at the Time of Itch Onset in Patients with Chronic Venous Disease

Contact Info

Product

Resources

About